• Revenue up ~100% YoY, driven by stronger US sales
• Continued progress on pipeline of complementary nerve repair products
• Successful IPO raising $7 million to fund growth

ReNerve Limited, a medical device company, has reported its 1HFY25 results, with revenue up ~100% year-over-year driven by stronger US sales of its NervAlign® Nerve Cuff product. The company continued to build its US sales infrastructure through partnerships with sales agents and distributors, and surgeon feedback confirmed the unique characteristics of the NervAlign® Nerve Cuff in terms of surgical convenience, patient safety and efficacy. During the period, ReNerve also made progress on its pipeline of complementary nerve repair products, including the NervAlign® Nerve Conduit and NervAlign® Nerve Guide Matrix. The company successfully showed that its Nerve Guide Matrix was able to re-establish functioning nerves in an animal model, and is actively continuing the development of this product with its partner Collagen Solutions.ReNerve also expanded its international footprint, signing distribution partnerships in Hong Kong and the Middle East, complementing its existing partnerships in New Zealand and Taiwan.The company completed a successful $7 million IPO in November 2024, which will be used to fund the progression of the Nerve Guide Matrix project, support the company's marketing program for the NervAlign® Nerve Cuff, and address working capital requirements.

ReNerve will continue to explore clinical studies to illustrate the functionality of its products and the clinical utility and benefits for surgeons and patients. The company also plans to further expand its international footprint and commercialize its pipeline of complementary nerve repair products.